The present disclosure relates to pharmaceutical compositions comprising hemp extract and a carrier. The present disclosure also relates to dosage forms and methods of treatment using the pharmaceutical compositions.

The invention relates to cannabinoid solutions in a mixture of sesame oil, amaranth oil and squalene. The invention also relates to pharmaceutical or nutraceutical formulations comprising said solutions.

The present invention provides compositions and methods for treating Prader Willi Syndrome (PWS). In particular, the present invention provides pharmaceutical compositions and formulations comprising cannabidiolic acid (CBDA) ester derivatives alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent, for use in treating PWS.

An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants includes one or more surfactants having a chemical structure that includes a polyethylene glycol moiety.

A botanical uni-sourced drug-loaded lipid-based nanoemulsion produced from one single medicinal herb such as Nigella sativa, Cannabis sativa, or Curcuma longa, wherein the herb acts as a comprehensive provider for the bioactive phytochemicals, oil phase, saponin surfactant, co-surfactant, proteins, and carbohydrates to produce the uni-sourced safe, clear, stable lipid-based drug delivery system. The nanoemulsion can be formulated into oral dosage form including nanoemulsion, microemulsion and liposomes, wherein the extraction and emulsification are carried out by the addition of water-soluble organic solvent, wherein the product can be further fermented and esterified for improved stability, wherein Nigella sativa uni-sourced nanocompositions are used as first-in-class oral formulation to relax coily hair targeting the arrector pili muscle in the hair root, anticancer, anti-tuberculosis, anti-COVID-19; and antiviral treatment, Cannabis nanocompositions are used for medical or recreational purposes, and Curcuma longa is used for nutraceutical and treatment purposes.

The present invention relates to compositions comprising active agents formulated for both buccal and gastric delivery wherein the composition also comprises one or more constituent, derivative or extract of cannabis and a further physiologically active agent.

The invention relates to a solid ?.sup.9-THC composition containing ?.sup.9-THC and a powder former and having a molar ratio of ?.sup.9-THC to powder former to form a flowable ?.sup.9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, ?-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid ?.sup.9-THC composition of the invention. The ?.sup.9-THC may be synthetic ?.sup.9-THC or may be extracted ?.sup.9-THC. The invention provides pharmaceutical or nutraceutical composition containing a solid ?.sup.9-THC composition of the invention and a pharmaceutically- or nutraceutically-acceptable carrier where ?.sup.9-THC is present in a pharmaceutically or nutraceutically effective amount. The invention also provides methods of treating a disease, disorder, or condition by administering to a patient in need thereof a therapeutically effective amount of a solid ?.sup.9-THC composition. A solid ?.sup.9-THC composition of the invention may also be incorporated into food and beverage products.

A new hemp cultivar Cherry king (Cannabis sativa L. cv. Cherry king) plant is obtained through open pollination using Cherry wine genetic resource as a seed parent, which is deposited under Accession Number KACC 88007BP and which has a higher content of cannabinoids than the seed parent, as well as a use thereof.

A new hemp cultivar Pinkpepper (Cannabis sativa L. cv. Pinkpepper) plant deposited under Accession Number KACC 88008BP has a higher content of cannabinoids than the seed and pollen parents. The new hemp cultivar Pinkpepper (Cannabis sativa L. cv. Pinkpepper) plant can be advantageously used as hemp for medical purpose, or obtaining hemp seeds or fibers.

Disclosed embodiments include systems and methods for obtaining desired organic compounds from harvested biomass. Some examples include an extraction vessel and a distillery system, where the extraction vessel is configured to wash harvested biomass with a process solvent to obtain a liquid extract, and where the distillery system is configured to distill the extract to separate the process solvent from the extract and obtain a distillate from the extract. Some embodiments additionally include a speedloader configured to load harvested biomass into the extraction vessel and a discharge gantry configured to remove processed biomass from the extraction vessel. In some embodiments, the extraction vessel, distillery system, speedloader, and discharge gantry are mobile and can be deployed in field at a harvest location.